Silexion Therapeutics (SLXN) Cash from Financing Activities (2023 - 2026)

Silexion Therapeutics' Cash from Financing Activities history runs 4 years deep, the most recent figure standing at $83000.0 for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 98.88% year-over-year to $83000.0; the TTM figure through Mar 2026 stood at $8.3 million (down 33.86% YoY), while the FY2025 annual figure was $15.6 million, up 206.43% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $83000.0, up from -$221000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $8.6 million in Q3 2025, with the low at -$221000.0 in Q4 2025.
• The 4-year median for Cash from Financing Activities is $1.4 million (2023), against an average of $2.7 million.
• Peak annual rise in Cash from Financing Activities reached 195.34% in 2025, while the deepest fall reached 110.12% in 2025.
• Silexion Therapeutics' Cash from Financing Activities stood at $522000.0 in 2023, then surged by 318.39% to $2.2 million in 2024, then slumped by 110.12% to -$221000.0 in 2025, then soared by 137.56% to $83000.0 in 2026.
• Business Quant data shows SLXN's Cash from Financing Activities at $83000.0 in Q1 2026, -$221000.0 in Q4 2025, and $8.6 million in Q3 2025.